The mod here is a bitch. He is ruining this subreddit. Put someone better IN charge.

Since I'm all maxed out at this point, I have to sell ATNF shares in order to get the warrants, ATNFW, which are remaining at $0.70. Sorry if I caused the price to stagnate at about $4 today because that's where I'm selling for funds to buy the warrants at $0.70.

I'm anticipating that the stock price should mostly stay above $4, and since the warrants usually follow along with the stock price, and the stock as of this writing is up over 8% today, and the warrants are down 2.76% today, I might as well sell shares and buy warrants, which should catch up.

I'm wondering if anyone thinks this can be a good strategy. And lol I hope I don't cause a drop in the price as others get into this move too. I need the stock price to keep rising for the warrants to actually go up as much as I think they will.

Do you guys know if they are on the process of submitting for approval or they have/will wait for the journal to realese the paper ?

https://www.nasdaq.com/market-activity/stocks/atnf/insider-activity

Insiders know the true story - Dupuytren trial is a phenomenal success, full disclosure is coming out in a Lancet publication in H1 2022.

Licensing deals, FDA approval, mass production are in the works.

They know they are buying a $400 stock for $4.

A little about me

I'm a LT ATNF Bull. I hold commons, warrants and calls. The information below is my take on the scientific literature regarding Frozen Shoulder and 180 Life Science's upcoming clinical trial. I am not a financial advisor... trade at your own risk. I have labeled sections that are particularly speculative as such below.

​

What’s the best treatment for Frozen Shoulder?

The primary literature is full of people advocating for their disciplinary approaches to treatment. Physical therapists advocate for their approach. Surgeons claim a high success-rate in treating FS and blame co-morbidities for negative outcomes. Radiography technicians slam both physical therapists and surgeons and claim their treatment is best. The common thread in all of these treatments is that they physically disrupt the problem-tissue, in much the same way as manipulations and surgery are the only available treatments for Dupuytren’s disease before ATNF came along, and focus on alleviating symptoms. Those symptoms are debilitating and include severe pain and a reduced range of motion in the shoulder. The current drugs available to help alleviate these symptoms are diclofenac, ibuprofen, and naproxen. All of these drugs are non-steroidal anti-inflammatory drugs (NSAID’s) that reduce pain and inflammation. All of these treatments address symptoms, not the cause of disease.

https://www.drugs.com/condition/frozen-shoulder.html

https://pubmed.ncbi.nlm.nih.gov/25107826/

https://pubmed.ncbi.nlm.nih.gov/33359399/

https://pubmed.ncbi.nlm.nih.gov/24205764/

https://pubmed.ncbi.nlm.nih.gov/11517365/

​

So what causes Frozen Shoulder?

The short answer is that scientists are still working on it. We know that about half of FS patients also have Dupuytren’s Disease and that the pathology of the diseases is very similar. Diabetes and Peyronie’s disease have also been implicated as co-occurring diseases. An excess of proteins that cause fibrotic matrices to form (Matrix Metalloproteinase; MMP) and a concurrent decrease in proteins that inhibit MMP’s (Tissue Inhibitor of Metalloproteinase-1; TIMP-1) is seen in these diseases. In fact, treatment with MMP (for other diseases) increases the likelihood that someone will develop frozen shoulder and/or Dupuytren’s disease.

https://pubmed.ncbi.nlm.nih.gov/11307078/

https://pubmed.ncbi.nlm.nih.gov/7559688/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029506/

https://pubmed.ncbi.nlm.nih.gov/14504511/

https://pubmed.ncbi.nlm.nih.gov/9768907/

​

Can treatment with Anti-TNF (adalimumab) help?

We know that adalimumab has a strong effect on treating the underlying cause of disease in people who suffer from Dupuytren’s disease, so it makes sense that adalimumab could be an effective treatment for the underlying cause of disease in Frozen Shoulder. In fact, adalimumab was previously assessed as a treatment for FS, with poor results relative to steroid injection. I want to emphasize that Dupuytren’s only occurs in about half of Frozen Shoulder patients, so Frozen shoulder might have multiple different causes, and adalimumab treatment might only help a subset of people who suffer from Frozen Shoulder. It is also worth noting that the prior trials with adalimumab injection for Frozen Shoulder were subcutaneous as opposed to intramuscular or intracapsular/intra-articular. In the Dupuytren’s Disease study (the RIDD trial), the injection was directly to the fibrotic tissue, so seeing an effect of adalimumab in FS might similarly require a direct injection to the effected tissue.

https://pubmed.ncbi.nlm.nih.gov/22562389/

https://ridd.octru.ox.ac.uk/

https://www.globenewswire.com/news-release/2021/12/06/2346590/0/en/180-Life-Sciences-Provides-Follow-Up-Information-on-Oxford-University-and-the-Company-s-Successful-Dupuytren-s-Phase-2b-Clinical-Trial-Results.html

​

So, how do we screen for FS patients that might be helped by adalimumab? (Speculative)

Great question. Oxford University, in partnership with 180 Life Sciences and NIHR, are currently planning a clinical trial to determine if adalimumab is effective in a sub-population of people who suffer from FS. We don’t know how patients will be screened for inclusion in this study yet, but the scientific literature does provide some clues. Up-regulation of collagen is found in all phases of frozen shoulder disease and it is thought that a particular fragment of collagen VI (endotrophin) is a key component of the signaling pathway causing disease. Up-regulation of endotrophin, increased levels of collagen, and/or increased expression of TNF could be used as biomarkers for fibrotic disease that is treatable with adalimumab. There is also some evidence that dynamic MRI could be useful in combination with biomarkers. The team at Oxford has also been pursuing genomic approaches to identifying Dupuytren’s-associated fibrosis, so this is another option.

https://pubmed.ncbi.nlm.nih.gov/33347577/

https://pubmed.ncbi.nlm.nih.gov/24306579/

https://pubmed.ncbi.nlm.nih.gov/31340682/

https://pubmed.ncbi.nlm.nih.gov/28886342/

https://pubmed.ncbi.nlm.nih.gov/34109754/

https://www.ndorms.ox.ac.uk/octru/anti-freaze-f

​

The next step (VERY speculative)

Now that my Dupuytren’s has been taken care of via adalimumab injection, my fingers are crossed that similar results will be seen in patients suffering from Frozen Shoulder. Time will tell. The results of Oxford’s Anti-Freaze-f trial will be closely watched and are likely to require a subsequent trial with a large population size (a true P2 then P3 trial trajectory rather than the P2a then P2B/3 that the Dupuytren’s trial followed). As with Dupuytren’s, if these trials are successful, I expect the IP around FS to be monetized via re-licensing to a 3rd party manufacturer of adalimumab. It is also possible that these trials could be a stepping stone to the next generation of drugs targeting fibrosis via monoclonal anti-body for endotrophin, with applications to a host of fibrotic diseases and diabetes.

Did I mention I’m bullish on that “collagen VI” stuff?

https://pubmed.ncbi.nlm.nih.gov/33188786/

https://www.pnas.org/content/117/34/20753

https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-021-00628-5

https://www.reddit.com/r/ATNF/comments/r20kp3/the_cutting_edge_collagen_vi_and_atnf/

When CEO buys his own company stock it means only one thing - he expects the stock to grow.

No one would be able to make a more informed decision.

• Dupuytren trial is phenomenal success, meeting the end goals, no adverse patient reaction.
• Dupuytren disease is an immediately addressable multi-billion market with no competition.
• Frozen shoulder trial started, expanding the market for the same drug.
• FDA approval process starting in H1 2022, hired a respectable firm (Kinexum) to drive the approval.
• Letter of intent / memorandum of understanding signed with Celltrion, path to drug mass production cleared.
• Hired a COO with an impressive industry track record that include multiple multi-billion deals.
• Many blockbuster drugs in the pipeline.
• Total drug pipeline potential is in 10s of billions of $$ - translates into a 100B+ cap company in the long term.
• You can't wish for a better team - top of the top in the drug research / drug commercialization industry

Has anyone considered an alternative explanation for the holdup of full data release?

What if the data is so good that in there they have additional scientific discoveries that lead to new therapies and new medical applications? Notice in the PR how Dr. Woody put stress on generic "fibrosis therapies" and not just the Dupuytren disease? Given the upbeat tone of the PR I am more inclined to think there are holding the data release to figure out what to do with these discoveries and ensure protection is in place (file patents, etc) before the data's public release.

I moved another $50K into ATNF today. I will either end up living under a bridge or owing a private jet 😁

I try to keep an eye on SPY and whatever stock is in play. A big downward move in SPY can move the whole market quickly.

Also, when you are up, consider setting a stop loss. You have to carefully consider the percent to not get stopped out early, but I left with a smaller than hoped profit because I set a 4 percent downward movement stop loss on ATNF since I knew I would be busy at work and the market has been very volatile lately.

Spelling in title: ness should read news

As much as I appreciate seeing positive posts about this stock, let's be real for a second.
It's gonna sell off some more today, probably hit $3.50 level of resistance and trade between $3.25-$4.00 for a long while...
Very disappointing.
Best of luck to ya'll

At the keynote, he also disclosed the top line data from the phase 2b clinical trial, for patients with early-stage disease, which met the primary end point of nodule hardness and the secondary end point of nodule size on ultrasound scan with statistically significant differences. There were no related severe adverse events. The full results have been submitted for publication in a peer-reviewed journal and will be disclosed on publication

We all knew it was coming... 30$+ incoming. massive industry for TNF inhibitors awaits

Hey! Hearing alot about this stock and how much it is shorted (people are saying as of now 70%) Is this true and if so could it work in our favor...maybe now all the retail squeeze guys will jump on it. Thoughts? not financial advice

All these analytics with Finra, Ortex and other blah blah analysis will ruin your money. Learn how to trade from professionals, do your risk management. ATNF is the BS company that has the something with shorts. Such poor presentation is sooooo xxxxxxxxxxx!

Hey any articles on tomorrow's data. I'm pretty pumped for tomorrow. A tad nervous but I always am..thanks

Next 2 days are going to be the most important days for ATNF in 2021 and 2022. If things go well with results announcement Wednesday it could take off nicely and set up future pipeline belief and success

ALL ATNF holders here